title: Will There Be a Cure for Ebola?
abstract: Despite the unprecedented Ebola virus outbreak response in West Africa, no Ebola medical countermeasures have been approved by the US Food and Drug Administration. However, multiple valuable lessons have been learned about the conduct of clinical research in a resource-poor, high risk-pathogen setting. Numerous therapeutics were explored or developed during the outbreak, including repurposed drugs, nucleoside and nucleotide analogues (BCX4430, brincidofovir, favipiravir, and GS-5734), nucleic acid-based drugs (TKM-Ebola and AVI-7537), and immunotherapeutics (convalescent plasma and ZMapp). We review Ebola therapeutics progress in the aftermath of the West Africa Ebola virus outbreak and attempt to offer a glimpse of a path forward.
authors.affiliation: US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702; email: anthony.p.cardile.mil@mail.mil.
authors.forename: Anthony P
authors.initials: AP
authors.lastname: Cardile
authors.affiliation: US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702; email: anthony.p.cardile.mil@mail.mil.
authors.forename: Travis K
authors.initials: TK
authors.lastname: Warren
authors.affiliation: US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702; email: anthony.p.cardile.mil@mail.mil.
authors.forename: Karen A
authors.initials: KA
authors.lastname: Martins
authors.affiliation: US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702; email: anthony.p.cardile.mil@mail.mil.
authors.forename: Ronald B
authors.initials: RB
authors.lastname: Reisler
authors.affiliation: US Army Medical Research Institute of Infectious Diseases, Frederick, Maryland 21702; email: anthony.p.cardile.mil@mail.mil.
authors.forename: Sina
authors.initials: S
authors.lastname: Bavari
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000241:Adenosine / Q000031:analogs & derivatives; D000249:Adenosine Monophosphate / Q000031:analogs & derivatives; D000354:Africa, Western / Q000453:epidemiology; D000409:Alanine / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology / Q000627:therapeutic use*; D004196:Disease Outbreaks / Q000517:prevention & control*; D029043:Ebolavirus / Q000187:drug effects* / Q000502:physiology; D019142:Hemorrhagic Fever, Ebola / Q000175:diagnosis / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D011684:Purine Nucleosides / Q000494:pharmacology / Q000627:therapeutic use; D011759:Pyrrolidines; D012265:Ribonucleotides / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D011684:Purine Nucleosides; D011759:Pyrrolidines; D012265:Ribonucleotides; C000606551:remdesivir; D000249:Adenosine Monophosphate; D000225:Adenine; D000241:Adenosine; D000409:Alanine; C517546:galidesivir
keywords: BCX4430; GS-5734; ZMapp; brincidofovir; convalescent plasma; favipiravir